Processa Pharmaceuticals (NASDAQ:PCSA) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Processa Pharmaceuticals (NASDAQ:PCSA) posted its earnings results on Thursday. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02, Zacks reports.

Processa Pharmaceuticals Stock Up 0.2 %

Processa Pharmaceuticals stock traded up $0.00 during mid-day trading on Thursday, reaching $0.43. 58,965 shares of the company’s stock were exchanged, compared to its average volume of 765,590. The business’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.97. The firm has a market capitalization of $1.39 million, a PE ratio of -0.13 and a beta of 0.75. Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Processa Pharmaceuticals in a research report on Thursday, December 5th.

Insiders Place Their Bets

In other Processa Pharmaceuticals news, CEO George K. Ng bought 87,200 shares of Processa Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $69,760.00. Following the completion of the transaction, the chief executive officer now directly owns 87,200 shares in the company, valued at $69,760. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Young bought 124,500 shares of Processa Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average price of $0.80 per share, with a total value of $99,600.00. Following the completion of the transaction, the insider now owns 205,405 shares of the company’s stock, valued at $164,324. This represents a 153.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 224,100 shares of company stock valued at $179,280 over the last ninety days. 13.00% of the stock is currently owned by insiders.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.